Vortioxetine for Cognitive Enhancement in Major Depression: From Animal Models to Clinical Research
Objectives: Vortioxetine has already shown its efficacy in the acute and long-term treatment of major depressive disorder (MDD) and its potential interest in the prevention of relapse. The aim of this study was to review the current status of knowledge regarding its cognitive effects.Methods: We con...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2019-11-01
|
| Series: | Frontiers in Psychiatry |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fpsyt.2019.00771/full |
| _version_ | 1818309173204484096 |
|---|---|
| author | Djamila Bennabi Emmanuel Haffen Vincent Van Waes |
| author_facet | Djamila Bennabi Emmanuel Haffen Vincent Van Waes |
| author_sort | Djamila Bennabi |
| collection | DOAJ |
| description | Objectives: Vortioxetine has already shown its efficacy in the acute and long-term treatment of major depressive disorder (MDD) and its potential interest in the prevention of relapse. The aim of this study was to review the current status of knowledge regarding its cognitive effects.Methods: We conducted a review of key data obtained from preclinical behavioral models and clinical trials in MDD focusing on vortioxetine-induced cognitive changes.Results: In animals, acute and chronic administration of vortioxetine improves performance on objective measures that cover a broad range of cognitive domains. In human, vortioxetine appears to be a useful treatment option in MDD patients with cognitive dysfunction.Conclusion: Vortioxetine constitutes a promising treatment for treatment of cognitive impairment in MDD, but its place in the therapeutic armamentarium still needs to be determined. |
| first_indexed | 2024-12-13T07:25:57Z |
| format | Article |
| id | doaj.art-47e9de519aa145d782aac70489d3298e |
| institution | Directory Open Access Journal |
| issn | 1664-0640 |
| language | English |
| last_indexed | 2024-12-13T07:25:57Z |
| publishDate | 2019-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Psychiatry |
| spelling | doaj.art-47e9de519aa145d782aac70489d3298e2022-12-21T23:55:18ZengFrontiers Media S.A.Frontiers in Psychiatry1664-06402019-11-011010.3389/fpsyt.2019.00771463116Vortioxetine for Cognitive Enhancement in Major Depression: From Animal Models to Clinical ResearchDjamila Bennabi0Emmanuel Haffen1Vincent Van Waes2Department of Clinical Psychiatry, INSERM, CHU de Besançon, Neurosciences, University Bourgogne Franche-Comté, FondaMental Foundation, Creteil, FranceDepartment of Clinical Psychiatry, INSERM, CHU de Besançon, Neurosciences, University Bourgogne Franche-Comté, FondaMental Foundation, Creteil, FranceLaboratory of Integrative and Clinical Neuroscience, University of Bourgogne Franche-Comté, Besançon, FranceObjectives: Vortioxetine has already shown its efficacy in the acute and long-term treatment of major depressive disorder (MDD) and its potential interest in the prevention of relapse. The aim of this study was to review the current status of knowledge regarding its cognitive effects.Methods: We conducted a review of key data obtained from preclinical behavioral models and clinical trials in MDD focusing on vortioxetine-induced cognitive changes.Results: In animals, acute and chronic administration of vortioxetine improves performance on objective measures that cover a broad range of cognitive domains. In human, vortioxetine appears to be a useful treatment option in MDD patients with cognitive dysfunction.Conclusion: Vortioxetine constitutes a promising treatment for treatment of cognitive impairment in MDD, but its place in the therapeutic armamentarium still needs to be determined.https://www.frontiersin.org/article/10.3389/fpsyt.2019.00771/fullmajor depressive disordervortioxetinecognitionhumansanimals |
| spellingShingle | Djamila Bennabi Emmanuel Haffen Vincent Van Waes Vortioxetine for Cognitive Enhancement in Major Depression: From Animal Models to Clinical Research Frontiers in Psychiatry major depressive disorder vortioxetine cognition humans animals |
| title | Vortioxetine for Cognitive Enhancement in Major Depression: From Animal Models to Clinical Research |
| title_full | Vortioxetine for Cognitive Enhancement in Major Depression: From Animal Models to Clinical Research |
| title_fullStr | Vortioxetine for Cognitive Enhancement in Major Depression: From Animal Models to Clinical Research |
| title_full_unstemmed | Vortioxetine for Cognitive Enhancement in Major Depression: From Animal Models to Clinical Research |
| title_short | Vortioxetine for Cognitive Enhancement in Major Depression: From Animal Models to Clinical Research |
| title_sort | vortioxetine for cognitive enhancement in major depression from animal models to clinical research |
| topic | major depressive disorder vortioxetine cognition humans animals |
| url | https://www.frontiersin.org/article/10.3389/fpsyt.2019.00771/full |
| work_keys_str_mv | AT djamilabennabi vortioxetineforcognitiveenhancementinmajordepressionfromanimalmodelstoclinicalresearch AT emmanuelhaffen vortioxetineforcognitiveenhancementinmajordepressionfromanimalmodelstoclinicalresearch AT vincentvanwaes vortioxetineforcognitiveenhancementinmajordepressionfromanimalmodelstoclinicalresearch |